Targeting KRAS-mutated Non-small Cell Lung Cancer
The U.S. FDA has granted accelerated approval to the first KRAS inhibitor, along with two companion diagnostics, for certain...
Progress Against Cancer
Home »
The U.S. FDA has granted accelerated approval to the first KRAS inhibitor, along with two companion diagnostics, for certain...
The FDA granted accelerated approval to the first targeted therapeutic and a companion diagnostic for certain adult patients with...
The FDA has approved an immunotherapeutic for certain patients with these cancers who had their cancer completely resected and...
The FDA has granted accelerated approval to an immunotherapeutic to be used in combination with a targeted therapeutic and...
The FDA has approved the targeted therapeutic loncastuximab tesirine-lpyl to treat certain adult patients with large B-cell lymphoma. The...
The FDA has granted accelerated approval to an immunotherapy to treat certain adult patients with endometrial cancer that tests...
The FDA has approved an immunotherapeutic in combination with chemotherapy to treat certain patients with gastric cancer, gastroesophageal junction...
The FDA granted accelerated approval to the targeted therapeutic sacituzumab govitecan to treat certain patients with the most common...
The FDA approved the first CAR T-cell therapy to treat certain adult patients with multiple myeloma. The U.S. Food...
the immunotherapeutic pembrolizumab in combination with chemotherapy WAS APPROVED to treat certain adult patients with esophageal cancer. The U.S....